



Please type a plus sign (+) inside this box

PTO/SB/08A (10-96)

Approved _____ through 10/31/99. OMB 0654-0031

Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

1 Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

DE BARK S Use substitute for form 1449A/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT				RECEIVED	
(use as many sheets as necessary)					
Sheet	1	of	1	Application Number	09/801,089
				Filing Date	March 8, 2001
				First Named Inventor	Phillips, David R.
				Group Art Unit	1644
				Examiner Name	Ewoldt, Gerald R.
				Attorney Docket Number	MP195-015P1RCPA1DV1M

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

She

3

1

Complete if Known

RECEIVED
MAY 22 1968

69 MAY 28 2003
2001
TECH CENTER 1600/2900
Gerald R.

FOREIGN PATENT DOCUMENTS

**Examiner
Signature**

3/25/04

Date
Considered

8


***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²See attached Kinds of U.S. Patent Documents. ³Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box



PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 6

Complete If Known

RECEIVED

MAY 28 2003

TECH CENTER 1600/2900

Application Number	09/801,089
Filing Date	March 8, 2001
First Named Inventor	Phillips, David R.
Group Art Unit	1644
Examiner Name	Ewoldt, Gerald R.
Attorney Docket Number	MP195-015P1RGPAT

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
<i>[Signature]</i>		Mikayama, T., et al. Molecular Cloning and Functional Expression of cDNA Encoding Glycocalyx Inhibiting Factor Proceedings of the National Academy of Sciences USA (90) 10056-10060 November 1993.
		Scarborough, et al., Design of potent and specific integrin antagonists. Peptide antagonists with high specificity for glycoprotein IIb-IIIa, pp60c-src, pp62c-yes, and the p21ras GTPase-activating protein with the membrane skeleton. Journal of Biological Chemistry 268:1066-1073 (1993).
		Fox, et al., On the role of the platelet membrane skeleton in mediating signal transduction Association of GP IIb-IIIa, pp60c-src, pp62c-yes, and the p21ras GTPase-activating protein with the membrane skeleton Journal of Biological Chemistry 268:25973-25984 (1993).
		Dorahy, et al., v Capture by chemical crosslinkers provides evidence that integrin alpha IIb beta 3 forms a complex with protein tyrosine kinases in intact platelets. Biochemistry Journal 309: 481-490 (1995).
		Argraves, W.S., et al., Fibulin, a novel protein that interacts with the fibronectin receptor beta subunit cytoplasmic domain. Cell 58:623-629 (1989).
		Bartfield, N.S., et al., The alpha v beta 3 integrin associates with a 190-kDa protein that is phosphorylated on tyrosine in response to platelet-derived growth factor. Journal of Biological Chemistry 268:17270-17276 (1993).
		Chen, Y.P., et al., Ser-752-->Pro mutation in the cytoplasmic domain of integrin beta 3 subunit and defective activation of platelet integrin alpha IIb beta 3 (glycoprotein IIb-IIIa) in a variant of Glanzmann thrombasthenia. Proceedings of the National Academy of Sciences USA 89:10169-10173 (1992).
		Clark, et al., Integrins and signal transduction pathways: the road taken. Science 268:233-239 (1995)
		Elmore, M. A., et al., Tyrosine-specific phosphorylation of gpIIa in platelet membranes. FEBS Letters 269:283-287 (1990).
<i>[Signature]</i>		Filardo, E.J., et al., Requirement of the NPXY motif in the integrin beta 3 subunit cytoplasmic tail for melanoma cell migration in vitro and in vivo. Journal of Cell Biology 130:441-450(1995).

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box

O 116
MAY 27 2003
SEARCHED & TRADEMAKED

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 6

Complete if Known

RECEIVED

Application Number	09/801,089
Filing Date	March 8, 2001
First Named Inventor	Phillips, David R. MAY 27 2003
Group Art Unit	1644
Examiner Name	Ewoldt, Gerald C. TECH CENTER 1600/2900
Attorney Docket Number	MPI95-015P1RPCATDVIM

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
KSP		Findik, D., et al., Platelet membrane glycoproteins IIb and IIIa are substrates of purified pp60c-src protein tyrosine kinase. FEBS Letters 262:1-4 (1990).	
		Fitzgerald, L., et al., Protein sequence of endothelial glycoprotein IIIa derived from a cDNA clone. Identity with platelet glycoprotein IIIa and similarity to "integrin". Journal of Biological Chemistry 262:3936-3939 (1987).	
		Ginsberg, M.H., et al., Inside-out integrin signaling. Current Opinion in Cell Biology 4:766-771 (1992).	
		Ginsberg, M.H., et al., Platelet integrins. Thrombosis and Haemostasis 70:87-93 (1993).	
		Ginsberg, M.H., et al., Dynamic regulation of integrins. Stem Cells, 13:38-46 (1995).	
		Grinblat, Y., et al., Functions of the cytoplasmic domain of the beta PS integrin subunit during Drosophila development. Development 120:91-102 (1994).	
		Hannigan, G.E., et al., Regulation of cell adhesion and anchorage-dependent growth by a new beta 1-integrin-linked protein kinase. Nature 379:91-96 (1996).	
		Hayashi, Y., et al. Expression and function of chicken integrin beta 1 subunit and its cytoplasmic domain mutants in mouse NIH 3T3 cells. Journal of Cell Biology 110:175-184 (1990).	
SJP		Hibbs, M.L., et al., The cytoplasmic domain of the integrin lymphocyte function-associated antigen 1 beta subunit: sites required for binding to intercellular adhesion molecule 1 and the phorbol ester-stimulated phosphorylation site. Journal of Experimental Medicine 174:1227-1238 (1991).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box



PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 3 of 6

Complete if Known

RECEIVED

Application Number	09/801,089
Filing Date	March 8, 2001 MAY 28 2003
First Named Inventor	Phillips, David R.
Group Art Unit	1644
Examiner Name	Ewoldt, Gerald R.
Attorney Docket Number	MPI95-015P1RCPA1DV1M

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
RJL		Hillary, C.A., et al., Phosphorylation of human platelet glycoprotein IIIa (GPIIIa). Disociation from fibrinogen receptor activation and phosphorylation of GPIIIa in vitro. Journal of Biological Chemistry 266:14663-14669 (1991).	
		Hirst, R., et al., Phosphorylation of the fibronectin receptor complex in cells transformed by oncogenes that encode tyrosine kinases. Proceedings of the National Academy of Sciences USA 83:6470-6474 (1986).	
		Horwitz, A., et al.,Interaction of plasma membrane fibronectin receptor with talin—a transmembrane linkage. Nature 320:531-533 (1986).	
		Huang, M-M., et al., Adhesive ligand binding to integrin alpha IIb beta 3 stimulates tyrosine phosphorylation of novel protein substrates before phosphorylation of pp125FAK. Journal of Cell Biology 122:473-483 (1993).	
		Hughes, P.E., et al., The conserved membrane-proximal region of an integrin cytoplasmic domain specifies ligand binding affinity. Journal of Biological Chemistry 270:12411-12417 (1995).	
		Hynes, R.O., Integrins: versatility, modulation, and signaling in cell adhesion. Cell 69:11-25 (1992).	
		Johansson, M.W., et al., Altered localization and cytoplasmic domain-binding properties of tyrosine-phosphorylated beta 1 integrin. Journal of Cell Biology 126:1299-1309 (1994).	
		Juliano, R.L., et al., Signal transduction from the extracellular matrix. Cell Biology 120:577-585 (1993).	
JKS		Kieffer, N., et al., Adhesive properties of the beta 3 integrins: comparison of GP IIb-IIIa and the vitronectin receptor individually expressed in human melanoma cells. Journal of Cell Biology 113:451-461 (1991).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

MAY 27 2003

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

Complete if Known

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

4

of

6

Application Number	09/801,089
Filing Date	March 8, 2001
First Named Inventor	Phillips, David R. MAY 28 2003
Group Art Unit	1644
Examiner Name	Ewoldt, John T. TECH CENTER 1600/2900
Attorney Docket Number	MPI95-015P1RCPA1D44

RECEIVED

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPTIAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
1582		LaFlamme, S.E., et al., Single subunit chimeric integrins as mimics and inhibitors of endogenous integrin functions in receptor localization, cell spreading and migration, and matrix assembly. Journal of Cell Biology 126:1287-1298 (1994).	
		Lanza, F., et al., cDNA cloning and expression of platelet p24/CD9. Evidence for a new family of multiple membrane-spanning proteins. Journal of Biological Chemistry. 266:10638-10645 (1991)	
		Luscinskas, et al. Integrins as dynamic regulators of vascular function. The FASEB Journal 8:929-938 (1994).	
		O'Toole, T.E., et al., Affinity modulation of the alpha IIb beta 3 integrin (platelet GPIIb-IIIa) is an intrinsic property of the receptor. Cell Regulation 1:883-893 (1990).	
		O'Toole, T.E., Regulation of integrin affinity states through an NPXY motif in the beta subunit cytoplasmic domain. Journal of Biological Chemistry 270:8553-8558 (1995).	
		Otey, C.A., et al., Mapping of the alpha-actinin binding site within the beta 1 integrin cytoplasmic domain. Journal of Biological Chemistry 268:21193-21197 (1993).	
		Parise, L.V., et al., Glycoprotein IIIa is phosphorylated in intact human platelets. Blood 75:2363-2368 (1990).	
		Phillips, D.R., et al. The platelet membrane glycoprotein IIb-IIIa complex. Blood 71:831-843 (1988).	
1582		Phillips, D.R., et al., GPIIb-IIIa: the responsive integrin. Cell 65:359-362 (1991).	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box

MAY 27 2003

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

Complete if Known

MAY 28 2003

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 5 of 6

Application Number	09/801,089
Filing Date	March 8, 2001
First Named Inventor	Phillips, David R.
Group Art Unit	1644
Examiner Name	Ewoldt, Gerald R.
Attorney Docket Number	MP195-015P1RCPA1DV1M

TECH CENTER 1600/2900

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS		
Examiner Initials*	Cite No. ¹	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.
<i>BSR</i>		Reszka, A.A., Identification of amino acid sequences in the integrin beta 1 cytoplasmic domain implicated in cytoskeletal association. Journal of Cell Biology 117:1321-1330 (1992).
		Rouslahti, E., Integrins. The Journal of Clinical Investigations 87:1-5 (1991).
		Schaller, M.D., et al., Focal adhesion kinase and paxillin bind to peptides mimicking beta integrin cytoplasmic domains. Journal of Cell Biology 130:1181-1187 (1995).
		Shattil, S.J., et al., Thrombosis and Haemostasis 73:1190 (1995).
		Shattil, S.J., et al., Changes in the platelet membrane glycoprotein IIb.IIIa complex during platelet activation. Journal Biological Chemistry 260:11107-11114 (1985).
		Smyth, S.S., et al., Regulation of vascular integrins. Blood 81:2827-2843 (1993).
		Diamond, M.S., The dynamic regulation of integrin adhesiveness. Current Biology 4:506-517 (1994).
		Tamkun, J.W., et al., Structure of integrin, a glycoprotein involved in the transmembrane linkage between fibronectin and actin. Cell 46:271-282 (1986).
<i>BSR</i>		Tapley, P., et al., Integrins isolated from Rous sarcoma virus-transformed chicken embryo fibroblasts. Oncogene 4:325-333 (1989).


*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box



PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 6

Complete if Known

RECEIVED

MAY 28 2003

TECH CENTER 1600/2900

Application Number	09/801,089
Filing Date	March 8, 2001
First Named Inventor	Phillips, David R.
Group Art Unit	1644
Examiner Name	Ewoldt, Gerald R.
Attorney Docket Number	MP185-015P1RCPA1DV1M

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. 1	Include the name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
GSR		Tcheng, J.E., et al., Multicenter, randomized, double-blind, placebo-controlled trial of the platelet integrin glycoprotein IIb/IIIa blocker Integrilin in elective coronary intervention. IMPACT Investigators. Circulation 91:2151-2157 (1995).	
		The EPIC Investigation, New England Journal of Medicine 330:956-961 (1994).	
		Vuori, K., et al., Mutation of the cytoplasmic domain of the integrin beta 3 subunit. Differential effects on cell spreading, recruitment to adhesion plaques, endocytosis, and phagocytosis. Journal of Biological Chemistry 270:9550-9557 (1995).	
		Ylanne, J., et al., Distinct functions of integrin alpha and beta subunit cytoplasmic domains in cell spreading and formation of focal adhesion. Journal of Cell Biology 122:223-233 (1993).	
		Lanza, Characterization of the human platelet glycoprotein IIIa gene. Comparison with the fibronectin receptor beta-subunit gene. Journal of Biological Chemistry, 265(30):18098-18103 (1990).	
GSR		Lukashev, Disruption of integrin function and induction of tyrosine phosphorylation by the autonomously expressed beta 1 integrin cytoplasmic domain. Journal of Biological Chemistry, 269(28):18311-18314 (1994).	

Examiner Signature

Examiner Signature

Date Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.

Please type a plus sign (+) inside this box →

PTO/SB/08B (10-96)

Approved for use through 10/31/99. OMB 0654-0031

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS

Examiner Signature	 3/25/04	Date Considered	
-----------------------	---	--------------------	--

***EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹Unique citation design number. ²Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, D.C. 20231.

DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, D.C. 20231.